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Abstract 
The synthesis of a series of benzimidazole-N-benzylpropan-1-amines and adenine-N-
benzylpropan-1-amines is described. Subsequent evaluation against two strains of the 
anaerobic bacterium Clostridium difficile was performed with three amine derivatives 
displaying MIC values of 16 g/mL. Molecular docking studies of the described 
amines determined that the amines interact within two active site pockets of 
Clostridium difficile methionyl tRNA synthetase with methoxy substituents in the 
benzyl ring and an adenine biaryl moiety resulting in optimal binding interactions. 
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Introduction 
The Clostridium difficile infection (CDI) rate has shown a dramatic increase 
over the past decade and this increase is associated with the emergence of 
hypervirulent strain B1/NAP1/0271. CDI can also now be found more commonly 
outside healthcare facilities and in previously low-risk groups, such as children, 
pregnant women, and individuals with irritable bowel syndrome2. Recently CDI has 
exceeded MRSA as the most common healthcare facility-associated infection3. First-
line treatment for CDI is usually metronidazole or vancomycin, for patients with 
severe infection, oral vancomycin is the preferred therapy as the clinical cure rate for 
vancomycin in patients with severe CDI was significantly better than that for 
metronidazole4. Unfortunately, recurrent disease occurs in 20 to 25% of patients 
receiving metronidazole and vancomycin5. For this reason there is a need to exploit 
other C. difficile targets in the development of new therapies. A promising target is 
aminoacyl-tRNA synthetase (aaRS). 
Research in our lab in Cardiff has focused on methionyl tRNA (MetRS) as an 
antibacterial target, using our published homology model of Clostridium difficile 
MetRS6 to aid the design process. Most MetRS inhibitors studied are against 
Staphylococcus aureus and Escherichia coli. These inhibitors are divided into either 
adenosine or non-adenosine analogues. Adenosine analogues (Figure 1) are thought to 
mimic the high-energy intermediate aminoacyl-AMP, thus blocking the aaRS pocket7. 
Non-adenosine analogues may have vast structural differences compared with the 
natural substrate aminoacyl-AMP, but they still have good enzyme inhibitory activity. 
The challenge for MetRS inhibitors however is not biochemical activity but whole-
cell activity. The most potent examples at the biochemical level, with IC50 values in 
the low nanomolar range, including oxazolone dipeptides and methionyl adenylate 
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isosteres, have shown good selectivity versus human MetRS but lack antibacterial 
activity in whole-cell assays8. 
Figure 1 here 
 
To date, REP3123 (Figure 1), a novel diaryldiamine, is the only documented 
selective C.difficile MetRS inhibitor with whole cell activity in a range of clinical 
C.diffcile isolates9. REP3123 is reported to have good in vitro activity and selectivity 
against C. difficile, while sparing other gut flora10
. 
We report the efficient synthesis (Scheme 1) and whole cell activity against C. 
difficile (Table 1) of a series of novel inhibitors incorporating pharmacophore 
elements of both REP3123 and adenosine analogues, namely: benzyl and biaryl 
moiety (adenine or benzimidazole) and flexible amine linker chain.  
 
Results and Discussion 
Chemistry 
Treatment of benzimidazole (1) or adenine (2) with potassium carbonate followed 
by the addition of tert-butyl(3-bromopropyl)carbamate resulted in N-alkylation 
products 3 and 4 in yields of 76 and 68% respectively. Subsequent deprotection of 
BOC under acidic conditions gave the trifluoroacetic acid salts 5 and 6 in quantitative 
and 93% yield respectively. Imine formation was achieved on base catalyzed reaction 
of 5 and 6 with a range of benzaldehydes, giving the imine derivatives 7 and 8 in 
variable yields. NaBH4 reduction of the imines gave the required benzimidazole and 
adenine N-benzylpropan-1-amines 9 and 10 in good yields. 
Scheme 1 here 
Microbiology 
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A stock solution of each amine was prepared in 5% DMSO at a concentration of 
256 g/mL. These were then diluted with nutrient broth to final concentrations of 128 
g/mL, 64 g/mL, 32 g/mL, 16 g/mL, 8 g/mL, 4 g/mL, 2 g/mL, 1 g/mL or 
0.5 g/mL and inoculated with a bacterial suspension of either C. difficile strain 1813 
or strain R20291. Growth was assessed after incubation at 37 oC for 48 h in an 
anaerobic cabinet. Metronidazole as a control showed an MIC of <0.5 g/mL for both 
C. difficile strain 1813 and R20291. 
Table 1 here 
Three amines 9e, 10a and 10e displayed MIC values of 16 g/mL against 
C.difficile strain 1813 (Table 1) and one of the imines 8d showed activity with an 
MIC value of 16g/mL. None of the imines or amines showed inhibitory activity 
against strain R20291. 
 
Molecular modeling 
Docking interactions of the imines and amines were explored using molecular 
modeling software. REP3123 had previously been shown to fit in two pockets within 
the C. difficile MetRS active site. Pocket 1 (the methionine binding pocket) has Ile12, 
Asp51, Ala230 and Trp227 as the main residues, while Glu55, Ser133 and Tyr225 
form an adjacent pocket (pocket 2) with Lys56 bridging the two pockets6,11
. 
Figure 2 here 
All the amines and imines had reasonable docking results based on both visual 
inspection of the poses and the docking score and occupied the two pockets 
previously observed for REP3123 (Figure 2). The adenine derivatives were found to 
give better interactions in terms of hydrogen bonding via the NH2 and the 4-methoxy 
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and 3,5-dimethoxy derivatives were able to better fill the two pockets with additional 
hydrogen bonding interactions between a methoxy group and Lys59 (Figure 3). Ile12 
was found to be the main key interaction in the methionine pocket, while Glu55, 
Lys59, Ala230 were found to be the main interactions in the adjacent pocket with 
Lys56 and Glu262 bridging these two pockets. 
Figure 3 here 
 
Conclusions 
This study provides some insight into the functionality required for improved 
binding interactions within the two pockets of the MetRS active site, although there is 
still scope for further extension within the pockets. The whole cell activity observed 
for the imine 8d and amines 9e, 10a and 10e is promising for further development, 
however the different inhibitory activity observed with the two C. difficile strains 
highlights the challenges of developing a MetRS inhibitor that can inhibit a range of 
C. difficile clinical isolates.  
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Figure 1. Adenosine analogue E.coli MetRS inhibitor and non-adenosine C. difficile 
MetRS inhibitor REP3123 and the natural substrate methionyl-AMP. 
 
 
 
 
 
 
Figure 2. 3,5-Dimethoxy amine derivative (10e) sitting in C. difficile MetRS two 
active site pockets. 
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Figure 3. 2D Ligand interaction between amine derivative 9e and the C.difficile 
MetRS active site residues. 
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Scheme 1. Reagents and conditions: (i) potassium carbonate, 18-crown-6, tert-
butyl(3-bromopropyl)carbamate, DMF, 60 ºC overnight (ii) TFA/DCM (iii) TEA, 
methanol, different benzaldehydes, overnight (iv) NaBH4, methanol, overnight. [a, R 
= H; b, R = 4-Cl ; c, R = 4-Br; d, R = 4-OMe ; e, R = 3,5-diOMe ] 
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Table 1. MIC (g/mL) against C. difficile strain 1813 
 
 
No. R MIC 
(g/mL) 
No. R MIC 
(g/mL) 
7a H > 128 8a H > 128 
7b 4-Cl > 128 8b 4-Cl > 128 
7c 4-Br >128 8c 4-Br 128 
7d 4-OMe > 128 8d 4-OMe 16 
7e 3,5-di-OMe 128 8e 3,5-di-OMe > 128 
 
 
No. R MIC 
(g/mL) 
No R MIC 
(g/mL) 
9a H 128 10a H 16 
9b 4-Cl 128 10b 4-Cl 128 
9c 4-Br 128 10c 4-Br 128 
9d 4-OMe 128 10d 4-OMe 128 
9e 3,5-di-OMe 16 10e 3,5-di-OMe 16 
Metronidazole <0.5 
 
  
 
 
 
 
 
 
